@article{ roldao_virus-like_2010,
  title = {Virus-like particles in vaccine development},
  volume = {9},
  issn = {1744-8395},
  doi = {10.1586/erv.10.115},
  abstract = {Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as, influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This article focuses on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production are discussed in the context of process control, monitorization and optimization. The main up- and down-stream technical challenges are identified and discussed accordingly. Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.},
  language = {eng},
  number = {10},
  journal = {Expert Review of Vaccines},
  author = {Roldão, António and Mellado, Maria Candida M. and Castilho, Leda R. and Carrondo, Manuel J. T. and Alves, Paula M.},
  month = {October},
  year = {2010},
  pmid = {20923267},
  keywords = {Animals, Biotechnology, Cell Line, Clinical Trials as Topic, Humans, Nanotechnology, Vaccination, Vaccines, Virus-Like Particle, Viral Vaccines, Virus Assembly, Virus Diseases},
  pages = {1149--1176}
}

{"_id":"GRn645eQhHLC98Hhy","bibbaseid":"roldo-mellado-castilho-carrondo-alves-viruslikeparticlesinvaccinedevelopment-2010","downloads":0,"creationDate":"2015-09-07T06:52:48.419Z","title":"Virus-like particles in vaccine development","author_short":["Roldão, A.","Mellado, M.<nbsp>C.<nbsp>M.","Castilho, L.<nbsp>R.","Carrondo, M.<nbsp>J.<nbsp>T.","Alves, P.<nbsp>M."],"year":2010,"bibtype":"article","biburl":"http://bibbase.org/zotero/vdec","bibdata":{"abstract":"Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as, influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This article focuses on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production are discussed in the context of process control, monitorization and optimization. The main up- and down-stream technical challenges are identified and discussed accordingly. Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.","author":["Roldão, António","Mellado, Maria Candida M.","Castilho, Leda R.","Carrondo, Manuel J. T.","Alves, Paula M."],"author_short":["Roldão, A.","Mellado, M.<nbsp>C.<nbsp>M.","Castilho, L.<nbsp>R.","Carrondo, M.<nbsp>J.<nbsp>T.","Alves, P.<nbsp>M."],"bibtex":"@article{ roldao_virus-like_2010,\n title = {Virus-like particles in vaccine development},\n volume = {9},\n issn = {1744-8395},\n doi = {10.1586/erv.10.115},\n abstract = {Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as, influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This article focuses on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production are discussed in the context of process control, monitorization and optimization. The main up- and down-stream technical challenges are identified and discussed accordingly. Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.},\n language = {eng},\n number = {10},\n journal = {Expert Review of Vaccines},\n author = {Roldão, António and Mellado, Maria Candida M. and Castilho, Leda R. and Carrondo, Manuel J. T. and Alves, Paula M.},\n month = {October},\n year = {2010},\n pmid = {20923267},\n keywords = {Animals, Biotechnology, Cell Line, Clinical Trials as Topic, Humans, Nanotechnology, Vaccination, Vaccines, Virus-Like Particle, Viral Vaccines, Virus Assembly, Virus Diseases},\n pages = {1149--1176}\n}","bibtype":"article","doi":"10.1586/erv.10.115","id":"roldao_virus-like_2010","issn":"1744-8395","journal":"Expert Review of Vaccines","key":"roldao_virus-like_2010","keywords":"Animals, Biotechnology, Cell Line, Clinical Trials as Topic, Humans, Nanotechnology, Vaccination, Vaccines, Virus-Like Particle, Viral Vaccines, Virus Assembly, Virus Diseases","language":"eng","month":"October","number":"10","pages":"1149--1176","pmid":"20923267","title":"Virus-like particles in vaccine development","type":"article","volume":"9","year":"2010","bibbaseid":"roldo-mellado-castilho-carrondo-alves-viruslikeparticlesinvaccinedevelopment-2010","role":"author","urls":{},"keyword":["Animals","Biotechnology","Cell Line","Clinical Trials as Topic","Humans","Nanotechnology","Vaccination","Vaccines","Virus-Like Particle","Viral Vaccines","Virus Assembly","Virus Diseases"],"downloads":0},"search_terms":["virus","particles","vaccine","development","roldão","mellado","castilho","carrondo","alves"],"keywords":["animals","biotechnology","cell line","clinical trials as topic","humans","nanotechnology","vaccination","vaccines","virus-like particle","viral vaccines","virus assembly","virus diseases"],"authorIDs":[],"dataSources":["JnJ2Whzgn25T7zFga"]}